Finance1 month ago
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1) Pivotal global Phase 3 PHOENIX trial of Tinlarebant...